Literature DB >> 34652632

The clinical spectrum of X-linked adrenoleukodystrophy: from Addison's-only in men to middle-age neurologic manifestations in women.

Lúcia Fadiga1, Miguel Melo2,3, Joana Saraiva2,3, Isabel Paiva2.   

Abstract

X-linked adrenoleukodystrophy (X-ALD) is caused by a mutation in the ABCD1 gene which encodes for a peroxisomal very long-chain fatty acid (VLCFA) transporter. Clinically, X-ALD can present a wide range of phenotypes, from slowly progressive myelopathy to rapid demyelination of brain white matter (cerebral X-ALD-CALD). Adrenocortical insufficiency (AI) occurs mainly in the pediatric age group, and it can be the first manifestation of the disease. Female carriers may also develop manifestations of myelopathy, but later in life. We present two cases of patients who show the heterogeneous clinical manifestations of X-ALD. Case 1 was a man with AI diagnosed at 6 years old and with the first manifestations of myelopathy at 44 years old, which led to the diagnosis of X-ALD. At 47 years, he developed rapidly progressive CALD. Case 2 was a woman with progressive spastic gait disturbance that started at 49 years old. The diagnosis of X-ALD was confirmed at 54 years old after the discovery of a family history of the disease. Mild progression of the neurologic manifestations was noted, but with no signs of AI nor CALD. She is currently 60 years old and under surveillance. We review the current knowledge on X-ALD as concerns its genetic and pathophysiological mechanisms, clinical presentations, diagnosis, treatment, and follow-up. This condition is a real diagnostic challenge. The early detection of AI and CALD, potentially life-threatening complications in men, is very difficult. The surveillance of these complications in female patients still raises controversy.
© 2021. Hellenic Endocrine Society.

Entities:  

Keywords:  ATP-binding cassette transporters; Adrenal insufficiency; Adrenoleukodystrophy; Myelopathy; Peroxisomal disorders

Mesh:

Substances:

Year:  2021        PMID: 34652632     DOI: 10.1007/s42000-021-00325-y

Source DB:  PubMed          Journal:  Hormones (Athens)        ISSN: 1109-3099            Impact factor:   2.885


  32 in total

Review 1.  Peroxisomal ABC transporters: structure, function and role in disease.

Authors:  Masashi Morita; Tsuneo Imanaka
Journal:  Biochim Biophys Acta       Date:  2012-02-17

2.  Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening.

Authors:  L Bezman; A B Moser; G V Raymond; P Rinaldo; P A Watkins; K D Smith; N E Kass; H W Moser
Journal:  Ann Neurol       Date:  2001-04       Impact factor: 10.422

3.  X-linked adrenoleukodystrophy in women: a cross-sectional cohort study.

Authors:  Marc Engelen; Mathieu Barbier; Inge M E Dijkstra; Remmelt Schür; Rob M A de Bie; Camiel Verhamme; Marcel G W Dijkgraaf; Patrick A Aubourg; Ronald J A Wanders; Bjorn M van Geel; Marianne de Visser; Bwee T Poll-The; Stephan Kemp
Journal:  Brain       Date:  2014-01-29       Impact factor: 13.501

4.  Molecular characterization of 21 X-ALD Portuguese families: identification of eight novel mutations in the ABCD1 gene.

Authors:  Carla P Guimarães; Manuela Lemos; Clara Sá-Miranda; Jorge E Azevedo
Journal:  Mol Genet Metab       Date:  2002-05       Impact factor: 4.797

5.  Adrenoleukodystrophy: increased plasma content of saturated very long chain fatty acids.

Authors:  H W Moser; A B Moser; K K Frayer; W Chen; J D Schulman; B P O'Neill; Y Kishimoto
Journal:  Neurology       Date:  1981-10       Impact factor: 9.910

Review 6.  Adrenoleukodystrophy - neuroendocrine pathogenesis and redefinition of natural history.

Authors:  Stephan Kemp; Irene C Huffnagel; Gabor E Linthorst; Ronald J Wanders; Marc Engelen
Journal:  Nat Rev Endocrinol       Date:  2016-06-17       Impact factor: 43.330

Review 7.  Adulthood leukodystrophies.

Authors:  Wolfgang Köhler; Julian Curiel; Adeline Vanderver
Journal:  Nat Rev Neurol       Date:  2018-01-05       Impact factor: 42.937

8.  X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management.

Authors:  Marc Engelen; Stephan Kemp; Marianne de Visser; Björn M van Geel; Ronald J A Wanders; Patrick Aubourg; Bwee Tien Poll-The
Journal:  Orphanet J Rare Dis       Date:  2012-08-13       Impact factor: 4.123

Review 9.  The genetic landscape of X-linked adrenoleukodystrophy: inheritance, mutations, modifier genes, and diagnosis.

Authors:  Christoph Wiesinger; Florian S Eichler; Johannes Berger
Journal:  Appl Clin Genet       Date:  2015-05-02

10.  Neurological impairment among heterozygote women for X-linked Adrenoleukodystrophy: a case control study on a clinical, neurophysiological and biochemical characteristics.

Authors:  Clarissa Troller Habekost; Pedro Schestatsky; Vitor Felix Torres; Daniella Moura de Coelho; Carmen Regla Vargas; Vitor Torrez; Jean Pierre Oses; Luis Valmor Portela; Fernanda dos Santos Pereira; Ursula Matte; Laura Bannach Jardim
Journal:  Orphanet J Rare Dis       Date:  2014-01-13       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.